Q-omics provides the consensus-scored ZNF83 profile across patient tissues and cancer cell-line models. ZNF83 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, ZNF83 is differentially expressed in 6, with the highest sampling consensus in KIRC. Additionally, ZNF83 RNA expression shows 20,203 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight BLCA, KIRC, and UVM as cancer lineages where ZNF83 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF83 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF83 survival associations across molecular data types. ZNF83 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF83 RNA expression–survival associations across cancer types. High ZNF83 expression shows unfavorable associations in KIRC, MESO, LGG, LUSC and COAD, but favorable associations in BLCA. The BLCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for ZNF83 RNA expression.
This table summarizes ZNF83 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for ZNF83. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF83 shows lower tumor expression in KICH and higher tumor expression in KIRC, CHOL, LIHC, KIRP and COAD. The KIRC box plot shows higher ZNF83 RNA expression in tumor versus normal tissue (log2 FC = +0.870, t-test p < 0.001).
This table shows molecular features associated with ZNF83 in patient tissues and cancer cell lines. In patient samples, ZNF83 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF83 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and BLOOD_Leukemia.
